Your browser doesn't support javascript.
loading
Projected impact of elbasvir/grazoprevir in patients with hepatitis C virus genotype 1 and chronic kidney disease in Vietnam.
Nwankwo, Chizoba; Corman, Shelby L; Elbasha, Elamin H.
Affiliation
  • Nwankwo C; Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA.
  • Corman SL; Health Economics and Outcomes Research, Pharmerit International, Bethesda, MD, USA. Electronic address: scorman@pharmerit.com.
  • Elbasha EH; Predictive and Economic Modeling, Merck & Co., Inc., North Wales, PA, USA.
J Infect Public Health ; 12(4): 502-508, 2019.
Article de En | MEDLINE | ID: mdl-30711348
BACKGROUND: Hepatitis C virus (HCV) infection is an important cause of morbidity and mortality in patients with chronic kidney disease (CKD). The objective of this study was to predict the impact of EBR/GZR on the incidence of liver and kidney related complications compared with no treatment (NoTx) and pegylated interferon plus ribavirin (pegIFN/RBV) in patients with CKD stage 4/5 in Vietnam. METHODS: We developed a mathematical model of the natural history of chronic HCV, CKD, and liver disease. Efficacy of EBR/GZR and pegIFN/RBV were derived from the C-SURFER trial and a meta-analysis, respectively. We calculated lifetime cumulative morbidity and mortality rates, including incidence of decompensated cirrhosis (DC), hepatocellular carcinoma (HCC), and life expectancy. RESULTS: Estimated lifetime incidence of DC was significantly reduced in patients receiving EBR/GZR (3.47%) compared to NoTx (18.14%) and pegIFN/RBV (9.01%). Estimated incidence of HCC was 1.02%, 21.64%, and 8.90%, and 1.02% in patients receiving EBR/GZR, NoTx, and pegIFN/RBV. EBR/GZR was estimated to extend life expectancy by 4.2 and 2.0 years compared with NoTx and pegIFN/RBV. CONCLUSIONS: Our model predicted that EBR/GZR will significantly reduce the incidence of liver-related complications and prolong life in patients with chronic HCV GT1 infection and CKD compared with NoTx or pegIFN/RBV.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Antiviraux / Quinoxalines / Benzofuranes / Hépatite C / Hepacivirus / Insuffisance rénale chronique / Imidazoles Type d'étude: Etiology_studies / Prognostic_studies / Risk_factors_studies Limites: Humans / Middle aged Pays/Région comme sujet: Asia Langue: En Journal: J Infect Public Health Sujet du journal: DOENCAS TRANSMISSIVEIS / SAUDE PUBLICA Année: 2019 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Antiviraux / Quinoxalines / Benzofuranes / Hépatite C / Hepacivirus / Insuffisance rénale chronique / Imidazoles Type d'étude: Etiology_studies / Prognostic_studies / Risk_factors_studies Limites: Humans / Middle aged Pays/Région comme sujet: Asia Langue: En Journal: J Infect Public Health Sujet du journal: DOENCAS TRANSMISSIVEIS / SAUDE PUBLICA Année: 2019 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Royaume-Uni